Injectable Cytotoxic Drugs Market Analysis

Injectable Cytotoxic Drugs Market Analysis

To get key market trends

  Download Free Sample

Based on drug class, the market is segmented into antimetabolites, vinca alkaloids, taxanes, anthracyclines, platinum compounds, alkylating agents, and other drug classes. The antimetabolites segment held the majority of market share in 2023 of about 44.2%.

• The dominating share of antimetabolites can be attributed to their wide use in anti-cancer therapies, as they are significantly effective against rapidly dividing cells associated with many types of cancer.  Efficacy against a wide range of cancer types, including leukemias, lymphomas, breast cancer, colorectal cancer, and various solid tumors has driven the adoption of antimetabolites in market.

   

• Growing prescriptions of antimetabolites such as methotrexate, fluorouracil (5-FU), cytarabine, and gemcitabine, owing to their proven efficacy and safety in cancer treatment is also contributing to the revenue growth of antimetabolites segment. As the antimetabolites have been extensively studied and clinically validated, these medications are considered standard-of-care treatments for certain cancer indications.

   

Based on distribution channel, the injectable cytotoxic drugs market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market with a revenue of about USD 4.8 billion in 2023.

• Hospitals commonly host extensive cancer centers or oncology departments that offer a wide range of cancer care services including chemotherapy and radiation therapy. As a result, majority of cancer treatments are performed across these inpatient settings. Hospital pharmacies play a crucial role in timely access to the medications such as injectable cytotoxic drugs that are used during these therapies. As a result, the hospital pharmacies contribute to a leading share in the market.

   

• Moreover, majority of injectable cytotoxic drugs requires skilled professional for their administration. Hospital pharmacies often have specialized oncology pharmacists and clinical staff with expertise in cancer treatment and chemotherapy administration. These professionals are trained to handle cytotoxic drugs safely, prepare chemotherapy regimens, monitor patients for adverse effects, and provide supportive care during treatment.

Based on application, the injectable cytotoxic drugs industry is classified into oncology, rheumatoid arthritis, multiple sclerosis, and other applications. The oncology segment secured a leading share of about 52.1% in 2023 and is anticipated to grow at 5.6% CAGR during the forecast period.

• Increasing incidence of cancer and growing demand for their therapeutic treatment has contributed to the leading share of oncology segment in 2023. World Health Organization in their 2024 report has projected that there will be over 35 million new cancer cases in 2050, marking a 77% rise from the estimated 20 million cases in 2022.

   

• Moreover, increasing approval for new injectable cytotoxic drug classes indicated for cancer treatment is also contributing to the leading share of oncology segment. For instance, in July 2023, US FDA approved dostarlimab in combination with chemotherapy for the treatment of MSI-H endometrial cancer.

North America injectable cytotoxic drugs market accounted for 42.2% of market share in global market in 2023 and is predicted to reach USD 6.6 billion by 2032.

• Presence of large number of pharmaceutical manufacturers in the U.S. offering advanced treatment options for cancer treatment such as new injectable cytotoxic drugs in combination with immunotherapies and radiotherapies is driving the revenue growth. Injectable cytotoxic drugs manufacturers are leveraging their manufacturing expertise, research and development capabilities, and marketing strategies to maintain dominance in the regional market, which has eased the availability of advanced injectable cytotoxic drug-based treatments in the region.

   

• Increasing approvals for injectable cytotoxic drugs by regulatory authorities such as U.S. FDA and Health Canada has eased the availability of advanced injectable cytotoxic drugs covering wide range of cancers including rare cancers.

   

The U.S. market was valued at USD 3.6 billion in 2023 and is anticipated to grow at a CAGR of 5.5% over the forecast period.

• Growing investments for the research and development of new injectable cytotoxic drugs using targeted small molecules, and growing demand for precision therapies is driving the revenue growth in U.S. market.

   

• Availability of reimbursement and coverage for injectable cytotoxic drugs used in chemotherapy are contributing to their increasing adoption in the country. The availability of reimbursement helps to reduce the out-of-pocket costs for patients which increases their access to treatment.

   

Germany injectable cytotoxic drugs market is expected to show significant growth during the forecast period.

• Germany boast one of the largest pharmaceutical markets in Europe, creating a favorable environment for the advancement of injectable cytotoxic drugs research and development. According to the Germany Trade & Invest (GTI), Germany stands out as a top contender in the European pharmaceutical market, evidenced by its substantial investments in R&D, innovative initiatives, and patent applications. Availability of substantial investments for the research and development in oncology drugs such as injectable cytotoxic drugs are propelling progress within the market in Germany.

   

• Moreover, increasing prevalence of multiple sclerosis and rheumatoid arthritis in Germany is also driving the demand for injectable cytotoxic drugs. According to a March 2022 article published by National Center for Biotechnology Information, the prevalence of multiple sclerosis increased from 0.27% in 2012 to 0.34% in 2019.

   

India injectable cytotoxic drugs industry is anticipated to grow remarkably over the coming years.

• Increasing prevalence of cancer and rheumatoid arthritis along with improved access to advanced treatment modalities such as injectable cytotoxic drugs-based combination therapies is driving the revenue growth in market in India. According to the Indian Council of Medical Research, cancer incidence in India is expected to rise by about 12.8% through 2025, in comparison to 2020. This rise in cancer incidence is expected to drive the demand for injectable cytotoxic drugs in India.

   

• Moreover, increasing growth in the local manufacturing of generic injectable cytotoxic drugs has eased their availability in the country. According to the Indian Brand Equity Foundation, India boasts largest number of U.S. FDA-compliant pharmaceutical plants outside the US with over 10,500 manufacturing facilities. As a result, increasing number of companies are outsourcing the production of generic injectable cytotoxic drugs to India, thereby expanding their presence in the country, which is contributing to the overall market growth of injectable cytotoxic drugs.